Katharina Iben, M.Sc.

Facts

E-Mail: katharina.iben2[at]uksh.de
Affiliations: Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
Address: Arnold-Heller-Str. 3, 24105 Kiel , Building QFZ U18
Supervisor: Dr. med. Lorenz Bastian

Education/Training

since October 2022PhD student at the Clinic for Internal Medicine II, Translational Leukemia Research, UKSH Kiel, Germany
2020 – 2022Master of Science, Biomedicine, Medical School Hannover, Germany
2017 – 2020Bachelor of Science, Nutritional Medicine, University of Lübeck, Germany

Research groups

Project-related publications

P1, P3, P4, P6, P7, Z

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL

Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.

PubMed (PMID: 42317203)
Hemasphere
2026
P1, P3, P4, Z, INF

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen BT, Hartmann AM, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller FJ, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus CD.

PubMed (PMID: 38153913)
Blood
2023

Participating Institutes